ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$20.20
+0.20%Oct 5, 2026, 14:00 UTC
Assembly Biosciences announced it will present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD The Liver Meeting 2026.
Source:Sep 8, 2026, 20:00 UTC
Assembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.
Source:Aug 13, 2026, 22:16 UTC
Assembly Biosciences reported a Q2 2026 loss of $0.20 per share, beating the Zacks Consensus Estimate of a $0.70 loss and improving from a $1.33 loss a year earlier.
Source:Jun 5, 2026, 00:00 UTC
Assembly Biosciences, Inc. elected Anthony E. Altig, Tomas Cihlar, Gina Consylman, Robert D. Cook II, and Sir Michael Houghton as directors effective June 4, 2026.